Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.
An effort was made to elucidate the limits of drug-activity tests in small animals. Human plasma kinetics of gentamicin, netilmicin, ticarcillin, ceftazidime, and ceftriaxone were approximated in normal and in granulocytopenic mice infected with various strains of Pseudomonas aeruginosa in the thigh muscle or intraperitoneally. The effect of such dosing on bacterial time-kill curves and on survival was compared with the effect of identical amounts of drug given as a single-bolus injection. With beta-lactams, a highly significant superiority of fractionated dosing (simulated human kinetics) over bolus injections (murine plasma kinetics) was demonstrated, whereas with aminoglycosides it was a single-bolus injection that tended to be more active. Thus, when tested in conventional small-animal models, aminoglycoside activity may be overestimated, whereas beta-lactam activity may be underestimated in respect to humans. These differences found in vivo most probably reflect the different pharmacodynamics between aminoglycosides and beta-lactam drugs (time-kill curves, dose-response curves, and postantibiotic effect) similar to those previously observed in vitro.
D000380:Agranulocytosis / Q000150:complications*; D000617:Aminoglycosides / Q000378:metabolism / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use*; D002442:Ceftazidime / Q000378:metabolism / Q000627:therapeutic use; D002443:Ceftriaxone / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D005839:Gentamicins / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D008657:Metabolic Clearance Rate; D051379:Mice; D009428:Netilmicin / Q000378:metabolism / Q000627:therapeutic use; D010538:Peritonitis / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D013982:Ticarcillin / Q000378:metabolism / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; D009428:Netilmicin; D002443:Ceftriaxone; D002442:Ceftazidime; D013982:Ticarcillin